The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment
Open accessAbstract
We describe a case of recurring Candida glabrata infection in a 68-year-old African-American female on caspofungin therapy. The initial isolate was susceptible, but isolates recovered during following relapses were not. All isolates were clonal, and high-MIC strains contained a mutation in the highly conserved hot spot 1 region of Fks1p.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been found in most clinically relevant Candida species, but is most common in C. glabrata with rates exceeding 10% at selected institutions.”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [10]
In the citing paper
“Echinocandin resistance has emerged over the recent years.”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [10]
In the citing paper
“Most are case reports or case series, which collectively document the potential of resistance development in almost all species that are not intrinsically susceptible (9–15).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [10]
In the citing paper
“Moreover, reports on acquired echinocandin resistance, defined as resistance among species that are normally susceptible, have emerged and today acquired resistance has been reported in single isolates belonging to most Candida species including C. albicans, C. dubliniensis, C. kefyr, C. glabrata, C. krusei, C. lusitaniae and C. tropicalis (9–15).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [10]
In the citing paper
“So far, clinically relevant acquired echinocandin resistance in Candida has never been detected in absence of FKS hot spot mutations.”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [10]
In the citing paper
“Target gene sequencing has become increasingly available and appropriate primers designed and published for the most common species (9–15).”
From Echinocandin resistance: an emerging clinical problem? (2014) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736
Resistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512
Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Self-citationMoudgal, V. V., Little, T., Boikov, D. A., & Vázquez, J. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.767-769.2005 · Cited by 241
Krogh-Madsen, M., Arendrup, M. C., Heslet, L., & Knudsen, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/500939 · Cited by 201
Multilocus Sequence Typing of Candidaglabrata Reveals Geographically EnrichedClades
Dodgson, A. R., Pujol, C., Denning, D. W., Soll, D. R., & Fox, A. J. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.12.5709-5717.2003 · Cited by 200
In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.760-763.2006 · Cited by 195
Laverdière, M., LALONDE, R. G., Baril, J.-G., Sheppard, D. C., Park, S., & Perlin, D. S. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl022 · Cited by 192
Katiyar, S. K., Pfaller, M. A., & Edlind, T. D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00349-06 · Cited by 189
Acquired resistance to echinocandins in Candida albicans: case report and review
Baixench, M.-T., Aoun, N. B. T., Desnos‐Ollivier, M., Garcia‐Hermoso, D., Bretagne, S., Ramires, S., Piketty, C., & Dannaoui, É. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm095 · Cited by 149
Flagged first, then by citations
Research works printed but not linked: 1
- M897. Abstr. 18th Intersci. Conf. Antimicrob. Agents Chemother. 2006
Cited by
Sorted by citations
Items 101–119 of 119
The Role of Resistance in Candida Infections: Epidemiology and Treatment
Sobel, J. D., & Akins, R. A. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-595-8_18 · Cited by 2
A Case of Micafungin-Hyposensitive Candida glabrata Due to FKS2 Gene Mutation
Inui, S., Nakamura, T., Tanabe, K., Ohno, H., Koike, C., Okuda, K., Nakata, C., FUJIMOTO, H., Ohkura, H., Miyazaki, Y., et al. (2011) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.85.49 · Cited by 2
Candida Infections: An Update on Host Immune Defenses and Anti-Fungal Drugs
Gao, N., & Chen, C. (2016) · doi:10.11979/idtm.201601005 · Cited by 2
Strategien bei Versagen einer antimykotischen Therapie auf Intensivstation
Arens, C., Bernhard, M., Koch, C., Heininger, A., Störzinger, D., Hoppe‐Tichy, T., Hecker, M., Grabein, B., Weigand, M. A., & Lichtenstern, C. (2015) · Der Anaesthesist · doi:10.1007/s00101-015-0072-0 · Cited by 1
Bopp, L. H., Baltch, A. L., Ritz, W. J., & Smith, R. P. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.08.001 · Cited by 1
Keiler, S. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-16 · Cited by 1
Fungal Drug Resistance and Pharmacologic Considerations of Dosing Newer Antifungal Therapies
Lewis, R. E., & Perlin, D. S. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-644-3_28
Mechanisms of Multidrug Resistance in Fungal Pathogens
Ferrari, S., & Sanglard, D. (2009) · Springer eBooks · doi:10.1007/978-3-642-03150-2_15
The Roles of Hsp90 and Calcineurin in Antifungal Drug Resistance
Singh, S. (2012) · TSpace (University of Toronto)
Fraser, M. (2019) · UWE Research Repository (UWE Bristol)
Multidrug Resistance Transcriptional Regulatory Networks in Candida
Rogers, P. D., & Barker, K. S. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch25
Perlin, D. S., & Hope, W. W. (2009) · Springer eBooks · doi:10.1007/978-90-481-2408-4_16
(2009) · Yeast · doi:10.1002/yea.1567
Perlin, D. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-46718-4_29
Warnock, D. W. (2011) · Wiley eBooks · doi:10.1128/9781555816728.ch126
Echinocandins for Prevention and Treatment of Invasive Fungal Infections
Johnson, M. D., & Mohr, J. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-14
Anderson, L., Schoch, J., Anastasia, E., Azeemi, F., Zeng, Z., Wang, V., Gorjifard, S., Matos-Nieves, A., Safer, J. F., Iqbal, S., et al. (2026) · Genome Biology and Evolution · doi:10.1093/gbe/evag271
Metadata
- Authors
- Cleary, J. D., Garcia-Effron, G., Chapman, S. W., & Perlin, D. S.
- Affiliations
- University of Mississippi (US)
- Public Health Research Institute, UMDNJ-New Jersey Medical School, Newark, New Jersey
- Rutgers New Jersey Medical School (US)
- Corresponding author
- Cleary, John D.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-06
- Volume
- 52
- Issue
- 6
- Pages
- 2263-2265
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2415792
- OpenAlex
- W2167509781
- Cited by
- 118
- References
- 15
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 3 · 2021: 4 · 2020: 3 · 2019: 6 · 2018: 1 · 2017: 4 · 2016: 3 · 2015: 6 · 2014: 9 · 2013: 5 · 2012: 16
- FWCI
- 11.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- Candida glabrata, candidemia, caspofungin, FKS1 mutations, fluconazole resistance, clonal isolates, recurrent fungal infection, antifungal susceptibility, echinocandin resistance
- MeSH terms
- Caspofungin, Aged, Antifungal Agents, Candidiasis, Female, Fungal Proteins, Glucosyltransferases, Humans, Membrane Proteins, Microbial Sensitivity Tests, Mutation, Fungemia, Fatal Outcome, Drug Resistance, Fungal, Candida glabrata, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
